Patient Support Services Contact Us
Expanding Our Mission to Immuno-oncology
More choice without compromise

Building on our success with UDENYCA® (pegfilgrastim-cbqv), we are now expanding our mission to immuno-oncology with Junshi Biosciences’ novel anti-PD-1 antibody, toripalimab.

Coherus is dedicated to expanding patient access to important medicines and delivering significant savings to the U.S. healthcare system.

About Coherus Immuno-oncology

I-O Begins Here: Late-Stage Anti-PD-1 Antibody

Our foundational first step in immuno-oncology begins with Junshi Biosciences’ anti-PD-1 antibody.

Learn More

Expanded Mission. Expanded Pipeline.

Our expanded immuno-oncology pipeline will be funded with cash flows generated by our commercial biosimilar business.

Learn More

Latest News

Coherus Announces Toripalimab Achieved Primary Endpoints of Progression Free Survival and Overall Survival in Interim Analysis of Phase 3 Clinical Trial in First-Line Esophageal Squamous Cell Carcinoma

Learn More

Coherus Announces Closing of Sale of Common Stock to Immuno-Oncology Partner Junshi Biosciences

Learn More

Junshi Biosciences and Coherus BioSciences Announce Initiation of Rolling Submission of BLA for Toripalimab to the U.S. FDA for the Treatment of Nasopharyngeal Carcinoma

Learn More

Coherus Issues Statement of Support for Passage of Biosimilar Legislation

WASHINGTON, D.C., April 14, 2021 -- Coherus BioSciences, Inc.’s (“Coherus”, Nasdaq: CHRS), CEO Denny Lanfear today issued a public statement of support regarding the passage of the Advancing Education on Biosimilars Act of 2021 (S.164).

View Now